×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RFL – rafael holdings, inc. class b (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RFL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/6
07:19 pm
rfl
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results [Yahoo! Finance]
Low
Report
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results [Yahoo! Finance]
11/6
07:14 pm
rfl
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Low
Report
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
10/7
12:15 pm
rfl
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
10/4
06:00 pm
rfl
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
10/2
11:15 am
rfl
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
9/23
01:15 pm
rfl
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
Medium
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
9/18
12:00 pm
rfl
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX
8/23
07:14 am
rfl
Rafael Holdings and Cyclo Therapeutics enter merger deal [Yahoo! Finance]
Low
Report
Rafael Holdings and Cyclo Therapeutics enter merger deal [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
09:43 am
rfl
Form DEF 14A Rafael Holdings, Inc. For: Jan 09
Low
Report
Form DEF 14A Rafael Holdings, Inc. For: Jan 09
11/7
06:04 am
rfl
Form 10-K Rafael Holdings, Inc. For: Jul 31
Low
Report
Form 10-K Rafael Holdings, Inc. For: Jul 31
11/7
06:02 am
rfl
Form 8-K Rafael Holdings, Inc. For: Nov 06
Low
Report
Form 8-K Rafael Holdings, Inc. For: Nov 06
10/30
09:05 am
rfl
Form NT 10-K Rafael Holdings, Inc. For: Jul 31
Medium
Report
Form NT 10-K Rafael Holdings, Inc. For: Jul 31
10/29
05:16 pm
rfl
Form 4 Rafael Holdings, Inc. For: Oct 25 Filed by: Polinsky David
Medium
Report
Form 4 Rafael Holdings, Inc. For: Oct 25 Filed by: Polinsky David
10/29
05:16 pm
rfl
Form 4 Rafael Holdings, Inc. For: Oct 25 Filed by: CONKLING WILLIAM
Medium
Report
Form 4 Rafael Holdings, Inc. For: Oct 25 Filed by: CONKLING WILLIAM
9/30
05:40 pm
rfl
Form SC 13D/A Rafael Holdings, Inc. Filed by: JONAS HOWARD S
Low
Report
Form SC 13D/A Rafael Holdings, Inc. Filed by: JONAS HOWARD S
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer
18.1%
4/28 MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia 13.6%
6/25 Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries 9.7%
12/5 Rafael Holdings to Present at LD Micro Main Event 9.3%
1/23 LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs 9.0%
11/21 Form DEF 14A Rafael Holdings, Inc. For: Jan 15 6.5%
12/3 Data on Rafael Pharmaceuticals’ CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition 6.4%
1/13 Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 4.2%
9/24 Form 4 Rafael Holdings, Inc. For: Sep 23 Filed by: Polinsky David 4.0%
5/16 Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala 3.4%
4/28 MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia 13.6%
6/25 Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries 9.7%
12/5 Rafael Holdings to Present at LD Micro Main Event 9.3%
1/23 LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs 9.0%
11/21 Form DEF 14A Rafael Holdings, Inc. For: Jan 15 6.5%
12/3 Data on Rafael Pharmaceuticals’ CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition 6.4%
1/13 Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference 4.2%
9/24 Form 4 Rafael Holdings, Inc. For: Sep 23 Filed by: Polinsky David 4.0%
5/16 Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night Gala 3.4%
TOP News Decliners
9/17
Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
-6.7%
8/8 Form 8-K Rafael Holdings, Inc. For: Aug 07 -6.3%
3/3 Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer -5.9%
5/13 Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations -5.5%
11/7 Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership -5.0%
3/5 Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results -4.8%
9/26 Form 8-K Rafael Holdings, Inc. For: Sep 23 -4.4%
12/9 Form 8-K Rafael Holdings, Inc. For: Dec 09 -4.2%
4/22 Form 4 Rafael Holdings, Inc. For: Apr 20 Filed by: JONAS HOWARD S -3.8%
10/2 Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer -3.4%
8/8 Form 8-K Rafael Holdings, Inc. For: Aug 07 -6.3%
3/3 Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer -5.9%
5/13 Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations -5.5%
11/7 Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership -5.0%
3/5 Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results -4.8%
9/26 Form 8-K Rafael Holdings, Inc. For: Sep 23 -4.4%
12/9 Form 8-K Rafael Holdings, Inc. For: Dec 09 -4.2%
4/22 Form 4 Rafael Holdings, Inc. For: Apr 20 Filed by: JONAS HOWARD S -3.8%
10/2 Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: